On July 11, 2022, MetiMedi Pharmaceutical Co., Ltd.’s main patent for its anticancer drug was successfully registered in Japan after passing the patent examination by the Japan Patent Office.

As a result, MetiMedi’s main anticancer drug patent has now been registered in a total of 55 countries, including the United States (2 cases), Japan, Korea, 34 member countries of the European Patent Convention (EPC), and 11 member countries of the Eurasian Patent Organization (EAPO).

Currently, MetiMedi is in the process of further expanding its patent coverage in 18 additional countries, including China.